Lilly drug slows Alzheimer's progression by 35% in trial

Using the commonly used dementia scale, trial results published last year showed that Eisai Co Ltd and Biogen Inc’s Leqembi reduced the rate of cognitive decline by 27% in patients with early Alzheimer’s.

Lilly said the incidence of serious brain swelling in the donanemab study was 1.6%, including two deaths attributed to the condition, and a third, after an incident of serious brain swelling. “There are risks in medicine, but I think when you look at these results in the context of a fatal life-threatening disease, are quite meaningful,” said Lilly Neuroscience executive Anne White in an interview with Reuters.Article content

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lilly drug slows Alzheimer's progression by 35 per cent in trialAn experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35 per cent in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a second effective treatment for the brain-wasting disease.
Source: CTVNews - 🏆 1. / 99 Read more »

Lilly drug slows Alzheimer's progression by 35% in trialAn experimental Alzheimer\u0027s drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a closely watched late\u002Dstage trial
Source: calgarysun - 🏆 63. / 52 Read more »